China Resources Double-Crane Pharmaceutical (SHA:600062) posted 2024 net profit attributable to shareholders of 1.63 billion yuan, down 2.6% from 1.67 billion yuan the previous year.
Earnings per share declined to 1.5838 yuan from 1.6306 yuan, according to a filing with the Shanghai bourse.
The company's revenue inched down 0.9% year over year to 11.2 billion yuan from 11.3 billion yuan.
The board declared a cash distribution of 0.371 yuan per share for 2024.
Shares of the company were down 3% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。